Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline.

Okonkwo DO, Puffer RC, Minhas DS, Beers SR, Edelman KL, Sharpless J, Laymon CM, Lopresti BJ, Benso S, Puccio AM, Pathak S, Ikonomovic MD, Mettenburg JM, Schneider W, Mathis CA, Mountz JM.

Front Neurol. 2019 Aug 2;10:831. doi: 10.3389/fneur.2019.00831. eCollection 2019.

2.

Association between Brain Amyloid, White Matter Hyperintensities and Hypometabolism, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.

Nadkarni NK, Tudorascu D, Campbell E, Snitz BE, Cohen AD, Halligan E, Mathis CA, Aizenstein HJ, Klunk WE.

J Gerontol A Biol Sci Med Sci. 2019 Apr 8. pii: glz088. doi: 10.1093/gerona/glz088. [Epub ahead of print]

PMID:
30957843
3.

Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women.

Wu M, Thurston RC, Tudorascu DL, Karim HT, Mathis CA, Lopresti BJ, Kamboh MI, Cohen AD, Snitz BE, Klunk WE, Aizenstein HJ.

Neurobiol Aging. 2019 Apr;76:141-150. doi: 10.1016/j.neurobiolaging.2018.11.020. Epub 2018 Dec 1.

PMID:
30711677
4.

Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.

Yan Q, Nho K, Del-Aguila JL, Wang X, Risacher SL, Fan KH, Snitz BE, Aizenstein HJ, Mathis CA, Lopez OL, Demirci FY, Feingold E, Klunk WE, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Cruchaga C, Kamboh MI.

Mol Psychiatry. 2018 Oct 25. doi: 10.1038/s41380-018-0246-7. [Epub ahead of print]

5.

Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Tudorascu DL, Anderson SJ, Minhas DS, Yu Z, Comer D, Lao P, Hartley S, Laymon CM, Snitz BE, Lopresti BJ, Johnson S, Price JC, Mathis CA, Aizenstein HJ, Klunk WE, Handen BL, Christian BT, Cohen AD.

Neurobiol Aging. 2019 Jan;73:171-176. doi: 10.1016/j.neurobiolaging.2018.09.030. Epub 2018 Sep 27.

PMID:
30359879
6.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

PMID:
30347188
7.

Sleep moderates the relationship between amyloid beta and memory recall.

Wilckens KA, Tudorascu DL, Snitz BE, Price JC, Aizenstein HJ, Lopez OL, Erickson KI, Lopresti BJ, Laymon CM, Minhas D, Mathis CA, Buysse DJ, Klunk WE, Cohen AD.

Neurobiol Aging. 2018 Nov;71:142-148. doi: 10.1016/j.neurobiolaging.2018.07.011. Epub 2018 Jul 26.

PMID:
30138767
8.

Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load.

Minhas DS, Price JC, Laymon CM, Becker CR, Klunk WE, Tudorascu DL, Abrahamson EE, Hamilton RL, Kofler JK, Mathis CA, Lopez OL, Ikonomovic MD.

Neuroimage Clin. 2018 Apr 4;19:182-189. doi: 10.1016/j.nicl.2018.04.007. eCollection 2018.

9.

The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods.

Tudorascu DL, Minhas DS, Lao PJ, Betthauser TJ, Yu Z, Laymon CM, Lopresti BJ, Mathis CA, Klunk WE, Handen BL, Christian BT, Cohen AD.

Alzheimers Dement (Amst). 2018 Apr 21;10:332-339. doi: 10.1016/j.dadm.2018.03.006. eCollection 2018.

10.

Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.

Frankle WG, Paris J, Himes M, Mason NS, Mathis CA, Narendran R.

Biol Psychiatry. 2018 Apr 15;83(8):707-714. doi: 10.1016/j.biopsych.2017.11.032. Epub 2017 Dec 7.

11.

Quantification of 5-HT1A and 5-HT2A receptor Binding in Depressed Suicide Attempters and Non-Attempters.

Mann JJ, Metts AV, Ogden RT, Mathis CA, Rubin-Falcone H, Gong Z, Drevets WC, Zelazny J, Brent DA.

Arch Suicide Res. 2019 Jan-Mar;23(1):122-133. doi: 10.1080/13811118.2017.1417185. Epub 2018 Mar 5.

PMID:
29281590
12.

Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Johnson SC, Klunk WE, Christian BT.

J Alzheimers Dis. 2018;61(2):631-644. doi: 10.3233/JAD-170720.

13.

An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.

Frankle WG, Robertson B, Maier G, Paris J, Asmonga D, May M, Himes ML, Mason NS, Mathis CA, Narendran R.

Synapse. 2018 Mar;72(3). doi: 10.1002/syn.22021. Epub 2017 Dec 13.

PMID:
29216407
14.

Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.

Zhao Y, Tudorascu DL, Lopez OL, Cohen AD, Mathis CA, Aizenstein HJ, Price JC, Kuller LH, Kamboh MI, DeKosky ST, Klunk WE, Snitz BE.

JAMA Neurol. 2018 Jan 1;75(1):88-96. doi: 10.1001/jamaneurol.2017.3029.

15.

Small-molecule PET Tracers for Imaging Proteinopathies.

Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE.

Semin Nucl Med. 2017 Sep;47(5):553-575. doi: 10.1053/j.semnuclmed.2017.06.003. Epub 2017 Jul 13. Review.

16.

Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Mailick MR, Klunk WE, Johnson SC, Christian BT.

Alzheimers Dement (Amst). 2017 May 23;9:1-9. doi: 10.1016/j.dadm.2017.05.001. eCollection 2017.

17.

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

Marquié M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Antón-Fernández A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M, Bien EA, Vanderburg CR, Costantino I, Makaretz S, DeVos SL, Oakley DH, Gomperts SN, Growdon JH, Domoto-Reilly K, Lucente D, Dickerson BC, Frosch MP, Hyman BT, Johnson KA, Gómez-Isla T.

Ann Neurol. 2017 Jan;81(1):117-128. doi: 10.1002/ana.24844.

18.

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.

Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, Mathis CA, Klunk WE, Chakrabarty A, Ironside J, Ismail A, Smith C, Thal DR, Beach TG, Farrar G, Smith AP.

Acta Neuropathol Commun. 2016 Dec 12;4(1):130.

19.

Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype.

Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, DeKosky ST, Klunk WE, Lopez OL.

JAMA Neurol. 2017 Jan 1;74(1):82-90. doi: 10.1001/jamaneurol.2016.3474.

20.

Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults.

Nadkarni NK, Lopez OL, Perera S, Studenski SA, Snitz BE, Erickson KI, Mathis CA, Nebes RD, Redfern M, Klunk WE.

J Gerontol A Biol Sci Med Sci. 2017 Mar 1;72(3):431-437. doi: 10.1093/gerona/glw211.

21.

Dopaminergic activity and altered reward modulation in anorexia nervosa-insight from multimodal imaging.

Bailer UF, Price JC, Meltzer CC, Wagner A, Mathis CA, Gamst A, Kaye WH.

Int J Eat Disord. 2017 May;50(5):593-596. doi: 10.1002/eat.22638. Epub 2016 Oct 18.

22.

SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.

Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K.

J Nucl Med. 2016 Aug;57(8):1316-22. doi: 10.2967/jnumed.116.174615. No abstract available.

23.

Tenascin-C Is Associated with Cored Amyloid-β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly.

Mi Z, Halfter W, Abrahamson EE, Klunk WE, Mathis CA, Mufson EJ, Ikonomovic MD.

J Neuropathol Exp Neurol. 2016 Sep;75(9):868-76. doi: 10.1093/jnen/nlw062. Epub 2016 Jul 21. Erratum in: J Neuropathol Exp Neurol. 2016 Dec;75(12):1190.

24.

[F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding.

Ikonomovic MD, Abrahamson EE, Price JC, Mathis CA, Klunk WE.

Ann Neurol. 2016 Aug;80(2):307-8. doi: 10.1002/ana.24706. Epub 2016 Jul 7. No abstract available.

25.

Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

Eisenmenger LB, Huo EJ, Hoffman JM, Minoshima S, Matesan MC, Lewis DH, Lopresti BJ, Mathis CA, Okonkwo DO, Mountz JM.

Semin Nucl Med. 2016 Jan;46(1):57-87. doi: 10.1053/j.semnuclmed.2015.09.003. Review.

PMID:
26687858
26.

Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688.

DeLorenzo C, Sovago J, Gardus J, Xu J, Yang J, Behrje R, Kumar JS, Devanand DP, Pelton GH, Mathis CA, Mason NS, Gomez-Mancilla B, Aizenstein H, Mann JJ, Parsey RV.

Transl Psychiatry. 2015 Dec 8;5:e693. doi: 10.1038/tp.2015.189.

27.

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.

Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.

Neuroimage Clin. 2015 Oct 14;9:592-8. doi: 10.1016/j.nicl.2015.10.007. eCollection 2015.

28.

Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities.

Goodheart AE, Tamburo E, Minhas D, Aizenstein HJ, McDade E, Snitz BE, Price JC, Mathis CA, Lopez OL, Klunk WE, Cohen AD.

Neuroimage Clin. 2015 Sep 29;9:479-83. doi: 10.1016/j.nicl.2015.09.009. eCollection 2015.

29.

Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study.

Snitz BE, Lopez OL, McDade E, Becker JT, Cohen AD, Price JC, Mathis CA, Klunk WE.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9. doi: 10.3233/JAD-150113.

30.

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T.

Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.

31.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

32.

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, Price JC, Foster NL, Wang AY.

Alzheimers Dement. 2015 Jul;11(7):757-71. doi: 10.1016/j.jalz.2015.05.001. Review.

33.

Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals.

Gregg NM, Kim AE, Gurol ME, Lopez OL, Aizenstein HJ, Price JC, Mathis CA, James JA, Snitz BE, Cohen AD, Kamboh MI, Minhas D, Weissfeld LA, Tamburo EL, Klunk WE.

JAMA Neurol. 2015 Sep;72(9):1021-8. doi: 10.1001/jamaneurol.2015.1359.

34.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.

35.

The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.

Lao PJ, Betthauser TJ, Hillmer AT, Price JC, Klunk WE, Mihaila I, Higgins AT, Bulova PD, Hartley SL, Hardison R, Tumuluru RV, Murali D, Mathis CA, Cohen AD, Barnhart TE, Devenny DA, Mailick MR, Johnson SC, Handen BL, Christian BT.

Alzheimers Dement. 2016 Apr;12(4):380-90. doi: 10.1016/j.jalz.2015.05.013. Epub 2015 Jun 13.

36.

Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC.

J Nucl Med. 2015 Aug;56(8):1199-205. doi: 10.2967/jnumed.114.152405. Epub 2015 Jun 4.

37.

Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults.

Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, McDade E, Price JC, Mathis CA, Klunk WE.

Am J Geriatr Psychiatry. 2015 Sep;23(9):985-93. doi: 10.1016/j.jagp.2015.01.008. Epub 2015 Feb 11.

38.

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA.

Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.

39.

Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, Salloway S, McDade E, Rossor MN, Ourselin S, Schofield PR, Masters CL, Martins RN, Weiner MW, Thompson PM, Fox NC, Koeppe RA, Jack CR Jr, Mathis CA, Oliver A, Blazey TM, Moulder K, Buckles V, Hornbeck R, Chhatwal J, Schultz AP, Goate AM, Fagan AM, Cairns NJ, Marcus DS, Morris JC, Ances BM.

JAMA Neurol. 2014 Sep;71(9):1111-22. doi: 10.1001/jamaneurol.2014.1654.

40.

Arterial stiffness and β-amyloid progression in nondemented elderly adults.

Hughes TM, Kuller LH, Barinas-Mitchell EJ, McDade EM, Klunk WE, Cohen AD, Mathis CA, Dekosky ST, Price JC, Lopez OL.

JAMA Neurol. 2014 May;71(5):562-8. doi: 10.1001/jamaneurol.2014.186.

41.

Positron emission tomography radioligands for in vivo imaging of Aβ plaques.

Mason NS, Mathis CA, Klunk WE.

J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):89-95. doi: 10.1002/jlcr.2989. Review.

42.

Amyloid burden and neural function in people at risk for Alzheimer's Disease.

Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, Hillmer AT, Wooten DW, Murali D, Barnhart TE, Hall LT, Racine AM, Klunk WE, Mathis CA, Bendlin BB, Gallagher CL, Carlsson CM, Rowley HA, Hermann BP, Dowling NM, Asthana S, Sager MA.

Neurobiol Aging. 2014 Mar;35(3):576-84. doi: 10.1016/j.neurobiolaging.2013.09.028. Epub 2013 Oct 23.

43.

Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.

Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJ, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK.

JAMA Neurol. 2014 Jan;71(1):23-31. doi: 10.1001/jamaneurol.2013.4847.

44.

Markers of cholesterol transport are associated with amyloid deposition in the brain.

Hughes TM, Lopez OL, Evans RW, Kamboh MI, Williamson JD, Klunk WE, Mathis CA, Price JC, Cohen AD, Snitz BE, Dekosky ST, Kuller LH.

Neurobiol Aging. 2014 Apr;35(4):802-7. doi: 10.1016/j.neurobiolaging.2013.09.040. Epub 2013 Oct 3.

45.

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.

Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9. doi: 10.1073/pnas.1317918110. Epub 2013 Nov 5.

46.

Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.

Hughes TM, Kuller LH, Barinas-Mitchell EJ, Mackey RH, McDade EM, Klunk WE, Aizenstein HJ, Cohen AD, Snitz BE, Mathis CA, Dekosky ST, Lopez OL.

Neurology. 2013 Nov 5;81(19):1711-8. doi: 10.1212/01.wnl.0000435301.64776.37. Epub 2013 Oct 16.

47.

Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture.

Mathis CA, Klunk WE.

Neuron. 2013 Sep 18;79(6):1035-7. doi: 10.1016/j.neuron.2013.09.001.

48.

Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.

Nebes RD, Snitz BE, Cohen AD, Aizenstein HJ, Saxton JA, Halligan EM, Mathis CA, Price JC, Kamboh MI, Weissfeld LA, Klunk WE.

Neuropsychologia. 2013 Sep;51(11):2202-9. doi: 10.1016/j.neuropsychologia.2013.07.017. Epub 2013 Aug 1.

49.

Development and screening of contrast agents for in vivo imaging of Parkinson's disease.

Neal KL, Shakerdge NB, Hou SS, Klunk WE, Mathis CA, Nesterov EE, Swager TM, McLean PJ, Bacskai BJ.

Mol Imaging Biol. 2013 Oct;15(5):585-95. doi: 10.1007/s11307-013-0634-y.

PMID:
23624948
50.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797. Epub 2013 Apr 17.

Supplemental Content

Loading ...
Support Center